论文部分内容阅读
目的探讨心房利尿钠肽转换酶(Corin)在妊娠期高血压疾病(hypertension disorders in pregnancy,HDP)发病中的作用,为HDP防治寻找潜在的防治靶点。方法收集乌鲁木齐市自治区人民医院北院2014年1月至2016年2月住院的HDP患者94例(HDP组),其中妊娠期高血压15例、轻度子痫前期34例、重度子痫前期32例、子痫13例。选取同期产检的正常产妇40例作为正常对照组。Corin酶的测定使用ELISA法。66例子痫前期患者根据随机数字法分为常规治疗对照组和丹红治疗研究组,每组33例。比较治疗后两组Corin表达、分娩时孕周、新生儿体重、围产儿死亡率、孕产妇死亡率和剖宫产率。结果正常对照组Corin酶表达水平为(186.4±31.7)pg/m L,显著高于HDP组的(142.4±19.5)pg/m L(P<0.05)。妊娠期高血压组、轻度子痫前期组、重度子痫前期组和子痫组中Corin表达水平分别为(167.2±25.3)pg/m L、(151.4±20.1)pg/m L、(132.3±18.2)pg/m L和(115.7±14.6)pg/m L,4组间差异有统计学意义(P<0.05)。常规治疗对照组和丹红治疗研究组在丹红治疗前Corin酶和24 h尿蛋白各项指标差异无统计学意义(P>0.05),经丹红治疗后丹红治疗研究组Corin酶的升高和24 h尿蛋白减低显著优于常规治疗对照组(P<0.05)。丹红治疗研究组的分娩时孕周、新生儿体重[(33.8±2.6)周、(1 792.5±224.2)g]显著优于常规治疗对照组[(32.4±2.4)周、(1 650.4±217.3)g](P<0.05)。丹红治疗研究组围产儿死亡率为0%,孕产妇死亡率为0%,剖宫产率为90.9%,与常规治疗对照组的3.0%、0%和93.9%比较差异无统计学意义(P>0.05)。结论 HDP孕妇体内存在Corin酶的异常低表达,丹红注射液可以显著升高Corin酶的表达,延长HDP孕周,增加新生儿体重,降低孕妇尿蛋白。
Objective To investigate the role of atrial natriuretic peptide-converting enzyme (Corin) in the pathogenesis of hypertensive disorders of pregnancy (HDP) and to find potential targets for prevention and treatment of HDP. Methods Ninety-four HDP patients (HDP group) were hospitalized in the north hospital of People’s Hospital of Urumqi from January 2014 to February 2016. Among them, there were 15 cases of HDP in pregnancy, 34 cases of mild preeclampsia, 32 cases of severe preeclampsia Cases, eclampsia in 13 cases. Select the same period of regular maternal examination of 40 cases as a normal control group. The Corin enzyme assay uses the ELISA method. 66 cases of preeclampsia patients were divided into conventional treatment group and Danhong treatment group according to random number method, with 33 cases in each group. The Corin expression, gestational age at birth, neonatal weight, perinatal mortality, maternal mortality and cesarean section rate were compared between the two groups after treatment. Results The expression of Corin in normal control group was (186.4 ± 31.7) pg / m L, significantly higher than that in HDP group (142.4 ± 19.5 pg / m L, P <0.05). The levels of Corin in gestational hypertension group, mild preeclampsia group, severe preeclampsia group and eclampsia group were (167.2 ± 25.3) pg / m L, (151.4 ± 20.1) pg / m L and 18.2) pg / m L and (115.7 ± 14.6) pg / m L, respectively. There was a significant difference between the four groups (P <0.05). There was no significant difference in the indexes of Corin enzyme and 24 h urinary protein before treatment with Danhong (P> 0.05). After treatment with Danhong, the Corin enzyme activity High and 24 h urinary protein decreased significantly better than the conventional treatment control group (P <0.05). At the gestational age of delivery in Danhong treatment group, the weight of newborn [(33.8 ± 2.6) weeks, (1792.5 ± 224.2) g] was significantly better than that of the routine treatment control group [(32.4 ± 2.4) weeks, (1 650.4 ± 217.3 ) g] (P <0.05). In the Danhong treatment group, the perinatal mortality rate was 0%, the maternal mortality rate was 0% and the cesarean section rate was 90.9%. There was no significant difference between the two groups (3.0%, 0% and 93.9%, respectively) P> 0.05). Conclusion The abnormal expression of Corin in pregnant women with HDP is low. Danhong injection can significantly increase the expression of Corin enzyme, prolong the gestational age of HDP, increase the weight of newborn and reduce the urine protein in pregnant women.